Abstract
Tuberculosis (TB) is the second cause of death from a single infectious agent, the M. tuberculosis bacillus. Nearly two billion people are infected and about 8.7 million new cases and 1.4 million deaths were reported by the World Health Organization (WHO) in 2013. Despite the availability of effective treatment, the alarming emergence of multidrug resistant (MDR) strains (with 310.000 estimated cases in 2011 among notified patients with pulmonary TB), simultaneously resistant to the two most effective anti-TB drugs, isoniazid (INH) and rifampicin, has urged the need to develop new molecular scaffolds, either structurally original or based on old and active drugs. The aim of this review is to summarize the current status of different QSAR based strategies for the design of novel anti-TB drugs based upon the most active anti-TB agent known, INH. A case study puts in evidence that the judicious application of quantitative structure- activity relationships can be successfully used to rationally design new INH-based derivatives, active against INH-resistant strains harboring mutations in the most frequent resistance related target (katG), and therefore develop candidate-compounds against MDR-TB, thus revisiting the unique effectiveness of INH against TB.
Keywords: Multidrug-resistance, tuberculosis, isoniazid, QSAR based-design, new antitubercular drugs.
Current Pharmaceutical Design
Title:QSAR Based Design of New Antitubercular Compounds: Improved Isoniazid Derivatives Against Multidrug-Resistant TB
Volume: 20 Issue: 27
Author(s): Filomena Martins, Cristina Ventura, Susana Santos and Miguel Viveiros
Affiliation:
Keywords: Multidrug-resistance, tuberculosis, isoniazid, QSAR based-design, new antitubercular drugs.
Abstract: Tuberculosis (TB) is the second cause of death from a single infectious agent, the M. tuberculosis bacillus. Nearly two billion people are infected and about 8.7 million new cases and 1.4 million deaths were reported by the World Health Organization (WHO) in 2013. Despite the availability of effective treatment, the alarming emergence of multidrug resistant (MDR) strains (with 310.000 estimated cases in 2011 among notified patients with pulmonary TB), simultaneously resistant to the two most effective anti-TB drugs, isoniazid (INH) and rifampicin, has urged the need to develop new molecular scaffolds, either structurally original or based on old and active drugs. The aim of this review is to summarize the current status of different QSAR based strategies for the design of novel anti-TB drugs based upon the most active anti-TB agent known, INH. A case study puts in evidence that the judicious application of quantitative structure- activity relationships can be successfully used to rationally design new INH-based derivatives, active against INH-resistant strains harboring mutations in the most frequent resistance related target (katG), and therefore develop candidate-compounds against MDR-TB, thus revisiting the unique effectiveness of INH against TB.
Export Options
About this article
Cite this article as:
Martins Filomena, Ventura Cristina, Santos Susana and Viveiros Miguel, QSAR Based Design of New Antitubercular Compounds: Improved Isoniazid Derivatives Against Multidrug-Resistant TB, Current Pharmaceutical Design 2014; 20 (27) . https://dx.doi.org/10.2174/1381612819666131118164434
DOI https://dx.doi.org/10.2174/1381612819666131118164434 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Comparison of Protease Inhibitor (PI) Resistance-Associated Mutations Between PI-Naive and PI-Experienced HIV-1 Infected Patients in Thailand Where Subtype A/E is Predominant
Current HIV Research Recent Advances in Medicinal Chemistry to Treat Tuberculosis – Part-I
Current Topics in Medicinal Chemistry Ferroquine: A New Weapon in the Fight Against Malaria
Current Medicinal Chemistry - Anti-Infective Agents Meet Our Editorial Board Member:
Current Medicinal Chemistry Nano-carriers for the Treatment of Tuberculosis
Recent Patents on Anti-Infective Drug Discovery Antiidiotype-Derived Killer Peptides As New Potential Tools to Combat HIV-1 and AIDS-Related Opportunistic Pathogens
Anti-Infective Agents in Medicinal Chemistry Recent Progress in the Identification and Development of InhA Direct Inhibitors of Mycobacterium tuberculosis
Mini-Reviews in Medicinal Chemistry Defining a Role for Mucosal Immunity in the Prevention and Pathogenesis of Respiratory Allergic Diseases
Current Immunology Reviews (Discontinued) Current Trends and Future Directions of Fluoroquinolones
Current Medicinal Chemistry Design, Synthesis, Molecular Docking, and Anticancer Evaluation of Pyrazole Linked Pyrazoline Derivatives with Carbothioamide Tail as EGFR Kinase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach
Current Drug Targets New Antimicrobial Approaches: Reuse of Old Drugs
Current Drug Targets Microwave-Assisted Synthesis of Benzo-fused Seven-membered Azaheterocycles
Mini-Reviews in Organic Chemistry Thermal Stability of Thermoanaerobacter tengcongensis Ribosome Recycling Factor
Protein & Peptide Letters Benzoylthioureas: Design, Synthesis and Antimycobacterial Evaluation
Medicinal Chemistry Type 2 Diabetes and its Impact on the Immune System
Current Diabetes Reviews Drug Discovery and Protein Tyrosine Phosphatases
Current Medicinal Chemistry Randomized Clinical Trials in Children - Ethical and Methodological Issues
Current Pharmaceutical Design Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinson’s Disease?
Current Medicinal Chemistry Crosstalk Between The Immune Receptors and Gut Microbiota
Current Protein & Peptide Science